GEP19991648B - Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity - Google Patents

Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity

Info

Publication number
GEP19991648B
GEP19991648B GEAP19973737A GEAP1997003737A GEP19991648B GE P19991648 B GEP19991648 B GE P19991648B GE AP19973737 A GEAP19973737 A GE AP19973737A GE AP1997003737 A GEAP1997003737 A GE AP1997003737A GE P19991648 B GEP19991648 B GE P19991648B
Authority
GE
Georgia
Prior art keywords
interferon
polyethylene glycol
pharmaceutical composition
conjugate
physiologically active
Prior art date
Application number
GEAP19973737A
Inventor
Vallejo Palleroni Alicia
Sebastian Bailon Pascal
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to GEAP19973737A priority Critical patent/GEP19991648B/en
Publication of GEP19991648B publication Critical patent/GEP19991648B/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.Technical Result Production of physiologically active poly¬ethylene glycol-interferon alpha conjugate with improved antiproliferative properties, increase in immunomodulatory and antiviral activity of the pharmaceutical composition. 2. Essence Physiologically active polyethylene glycol-interferon-alpha conjugate represents the compounds of the general formula: wherein R and Rare independently lower alkyl; X is NH or O; n and n are integers having a sum of from 600 to 1500; and the average molecular weight of the polyethylene glycol units in said conjugate is from about 26.000 daltons to about 66.000 daltons which is obtained by covalenty linking polyethylene glycol to interferon-alpha at pH 8-9 of the reaction mixture at temperature 4C. Pharmaceutical composition having immuno¬modu¬latory and antiviral actifity comprises said conjugate in effective amount and therapeutically acceptable additive. 3. Field of Application Organic chemistry, pharmacology. 2 ind. cl., 4 Tables, 6 fig.
GEAP19973737A 1997-05-05 1997-05-05 Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity GEP19991648B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GEAP19973737A GEP19991648B (en) 1997-05-05 1997-05-05 Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GEAP19973737A GEP19991648B (en) 1997-05-05 1997-05-05 Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity

Publications (1)

Publication Number Publication Date
GEP19991648B true GEP19991648B (en) 1999-06-14

Family

ID=81926190

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19973737A GEP19991648B (en) 1997-05-05 1997-05-05 Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity

Country Status (1)

Country Link
GE (1) GEP19991648B (en)

Similar Documents

Publication Publication Date Title
KR940003969A (en) Fiji (PEG) -interferon conjugate
RS49533B (en) Interferon conjugates
HU9601247D0 (en) Improved interferon polymer conjugates
ATE227317T1 (en) SOLUTION POLYMERIZATION OF HIGH MOLECULAR POLYPHOSPHORE ESTERS IN TOLUENE
IL132122A0 (en) Biodegradable polymers chain-extended by phosphates compositions articles and methods for making and using the same
EP0340741A3 (en) Polyethylene glycol derivatives, modified peptides and production thereof
MY126776A (en) Erythropoietin conjugates with polyethylenglycol
GEP20063860B (en) Chemically-modified human growth hormone conjugates
MXPA00006547A (en) Erythropoietin derivatives.
TW218874B (en)
NO974678D0 (en) Heterotelechelic block copolymer and a process for its preparation
ATE159036T1 (en) COPOLYMERS BASED ON N-ALKYLACRYLAMIDE, THEIR PRODUCTION AND THEIR USE AS THICKENERS IN SHAMPOO COMPOSITIONS
WO2003059973A3 (en) Block copolymers
AU3855297A (en) Pharmaceutical composition for treating papillomavirus tumours and infection
GR3018835T3 (en) Solid polymeric electrolyte and devices which incorporate it
KR880000511A (en) Thermoplastic molding compositions
AU1995688A (en) Carbamates and Bis-carbamates, their production and use as fuel additives
ATE191728T1 (en) CROSS-LINKED POLYASPRICIC ACID AND SALTS
EP0480999A4 (en) Antimicrobial polymeric bisbiguanides
GEP19991648B (en) Physiologically Active Polyethylene Glycol-Interferon-Alpha Conjugate, Method for its Production, Pharmaceutical Composition Having Immunomodulatory and Antiviral Activity
ATE67932T1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUPPOSITORIES.
DE69920221D1 (en) POLYPEPTIDE-POLYMER CONJUGATE
CA2165305A1 (en) Fuel additive compositions containing an aliphatic amine, a polyolefin and an aromatic ester
JPS55135590A (en) Modified asparaginase and uricase and their preparation
EP0459624A3 (en) Galactosamine-substituted poly-omega-substituted-l-glutamic and/or-aspartic acid